Back to Results

Zheng "Frank" Zhou, MD, PhD Accepting New Patients

Programs + Specialties
Training + Education University of Massachusetts; UMass Memorial Medical Center, Hematology/Oncology Fellow Training at Northwestern Memorial Hospital
Board Certifications Hematology, Medical Oncology, Internal Medicine
NPI # 1659531770
Gender Male
Accepted Insurances View Accepted Insurances at Tufts Medical Center

Tufts Medical Center
800 Washington St.
South Building, Floor 8
Boston, MA 02111
Phone #: 617-636-6227
Fax #: 617-636-8538

Northwestern Medicine Jameson Research Prize for Outstanding Research Contributions (2014)
ECOG/ACRIN 12th Annual ECOG/Sanofi-Aventis Oncology Young Investigator Symposium Award (2012)
National Institute of Health (T32 CA 79447-15) Clinical Fellow Research Training Grant (2012-2014)
ASCO-AACR 2013 Vail Clinical Trial Workshop Selected Attendee and Protocol
Illinois Medical Oncology Society Annual Fellow Research Award.

Zhou Z, Nath R, Cerny J, Wang H-L, Saber W, et al. (2020) Reduced Intensity Conditioning for Acute Myeloid Leukemia using Melphalan versus Busulfan based Regimens – A CIBMTR Report. Blood Advances 4(13): 3180–90.

Zhou Z, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson AL, et al. (2016) High body mass index in elderly DLBCL patients treated with rituximab containing therapy compensates for negative impact of male sex. JNCCN. 14:1274-81

Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter, JN, Licht JD, et al. (2015) Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma (DLBCL) independent of cell of origin and EZH2 codon 641 mutation. Leukemia and Lymphoma. 56(10):2895-901.

Zhou Z, Sehn L, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson AL, Winter JN et al. (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B cell lymphoma treated in the rituximab era. Blood 123(6): 837-42

Zhou Z, Peretz Y, Chang Y, Li X, Miao DS, and Prud'homme GJ (2003) Intramuscular Gene Transfer of Soluble B7-1/IgG1 Fusion cDNA Induces Potent Antitumor Immunity as an Adjuvant for DNA Vaccination. Cancer Gene Therapy 10(6): 491-9

Zhou Z, and Lam P (2007). Discussion on Use of Propensity Score in Non-randomized Clinical Studies in Medical Device. Journal of Biopharmaceutical Statistics 17(1):25-7

Zhou Z, Rahme E, Abrahamowicz M, Pilote L (2005). Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods. American Journal of Epidemiology 162(10):1016-23

American Society of Hematology (ASH)
American Society of Transplantation and Cellular Therapy (ASTCT)
Foundation for the Accreditation of Cellular Therapy (FACT)
American College of Physicians (ACP)